|
Profile
|
Delegates :
Kohei Yamada |
|
Incorporated :
September 1 , 2014 |
Paid in Capital :
100 Million yen |
Employees :
38 人 |
Address :
Technoport Kamata Center Building, 2-16-1 Minami-Kamata, Ota-ku TOKYO
〒144-0035
|
TEL/FAX :
+81-3-6715-9101 / +81-3-6715-9120 |
URL：
https://www.smccro-lab.com/ |
Attachment :
|
Mission/Background :
SMC Laboratories, Inc. is a specialized preclinical contract research organization (CRO) providing pharmacology, efficacy, and translational research services in MASH/MASLD, liver fibrosis, hepatocellular carcinoma (HCC), pulmonary fibrosis (IPF), renal fibrosis, inflammatory bowel disease (IBD), autoimmune diseases, and immuno-oncology. Leveraging advanced disease models, including the proprietary STAM(TM) mouse model that reproduces progression from fatty liver disease to MASH, fibrosis, and liver cancer, SMC supports target validation, proof-of-concept (PoC), mechanism-of-action studies, biomarker evaluation, and drug candidate assessment. With extensive experience partnering with pharmaceutical, biotechnology, and academic organizations worldwide, SMC helps accelerate the discovery and development of innovative therapeutics through high-quality preclinical research. |
|
Technology & Business
|
SMC Laboratories, Inc. is a contract research organization (CRO) providing preclinical pharmacology and efficacy evaluation services to pharmaceutical companies, biotechnology firms, and academic institutions.
The company specializes in therapeutic areas including MASH, liver fibrosis, hepatocellular carcinoma (HCC), pulmonary fibrosis (IPF), renal fibrosis, inflammatory bowel disease (IBD), and immuno-oncology. SMC offers efficacy studies, mechanism-of-action analyses, and biomarker evaluations using highly translational disease models that closely mimic human pathophysiology.
Its proprietary STAM(TM) mouse model reproduces the progression from fatty liver disease to MASH, fibrosis, and liver cancer, and has been widely utilized in drug discovery programs worldwide.
In addition to study execution, SMC provides comprehensive support throughout the drug development process, including development strategy planning, assay and model development, and collaborative research partnerships.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Preclinical Efficacy Studies Using STAM(TM) Mice
|
Launched
|
In vivo pharmacology studies targeting MASH/NASH, liver fibrosis, and hepatocellular carcinoma using a proprietary disease model
|
Expansion of global pharmaceutical and biotech collaborations
|
STAM(TM)-HCC/IO+ Model Studies
|
Launched
|
Advanced preclinical evaluation of immunotherapies and molecular targeted drugs for liver cancer
|
Increase adoption in immuno-oncology drug development programs
|
Preclinical Study Design & Consulting Services
|
Launched
|
Consulting-oriented support from study design through data interpretation
|
Support early-stage pipelines and new modality development
|
|
|
|
|
|
|
|
|
|
Highlights
|
In 2025, SMC Laboratories strengthened its leadership in liver disease research by exhibiting and presenting at APASL, a major international MASH and hepatology conference. The company also appointed renowned liver disease expert Prof. Ekihiro Seki to its Scientific Advisory Board and secured a patent for the STAM-IO model, expanding its capabilities in immuno-oncology and MASH-related HCC drug discovery support.
|
|
Hot news
|
SMC Laboratories welcomes collaborative and contract research opportunities in MASH, liver fibrosis, HCC, pulmonary fibrosis, and renal fibrosis. Using proprietary disease models, including the STAM（TM) mouse model, SMC supports drug discovery from target validation through preclinical proof-of-concept (PoC) studies. The company partners with pharmaceutical, biotechnology, and academic organizations to accelerate the development of innovative therapies.
|
|
Alliance strategy
|
SMC Laboratories, Inc. provides preclinical drug discovery support using advanced disease models for MASH, liver fibrosis, HCC, pulmonary fibrosis, renal fibrosis, IBD, and immuno-oncology. The company collaborates with pharmaceutical, biotechnology, and academic partners on target validation, proof-of-concept (PoC), and biomarker research. SMC also offers its proprietary STAM(TM) mouse model and fibrosis-focused platforms to accelerate therapeutic development.
|
|
|